Huarun Pharmaceutical (300110.SZ) participates in the "3+N" alliance in Beijing-Tianjin-Hebei region, and is selected to continue the procurement of some western and traditional Chinese medicine in a volume-based linkage manner.

Zhixun Finance APP reported that Huaren Pharma (300110.SZ) announced that the company and its wholly-owned subsidiaries Guangxi Yuyuan Pharmaceuticals Co., Ltd. and Huaren Pharmaceuticals (Rizhao) Co., Ltd. recently actively participated in the bidding for the "3+N" Alliance in the Beijing-Tianjin-Hebei region for the follow-up procurement of some Western medicines and traditional Chinese medicines (project number: LH-YD2025-1). According to the selection results recently announced by the Tianjin Medical Procurement Center, the company and its wholly-owned subsidiaries' products of mixed sugar electrolyte injections, citalopram hydrobromide injection, and hydroxyethyl starch 130/0.4 sodium chloride injection were selected for this follow-up procurement.